Top 15 Healthcare Stocks by Marvin Opportunity Score
Marvin's rules picked 15 Healthcare stocks, led by Nutex Health, Arrowhead and Travere, ranked by Opportunity score among companies with solid Business Quality. Many are still unprofitable, so check the figures.
Healthcare covers very different businesses, including drug developers, medical device makers, diagnostics firms, care facilities and health plans. This list of 15 stocks comes from Marvin's rules, which compare each company with others in its own industry.
The figures differ a lot from one pick to the next. Some companies are already profitable, with strong margins and modest debt. Others, mostly biotechnology and diagnostics firms, report large revenue growth but still lose money. A very high growth rate often reflects one unusual year, so read it alongside the margins.
Use the list as a starting point for your own research, not as a recommendation. Scores describe how a company compares with its industry peers today and say nothing about what happens next.
The list
How Marvin ranked these stocks
Marvin started with companies above a minimum size and ranked them by Marvin scores, which are relative to each company's own industry. Within the Healthcare sector, stocks are ordered by Opportunity score, highest first. Only companies with a Business Quality score above a set minimum are included, and the list limits how many come from any one industry. A high score therefore means a company looks strong against its industry peers, not against the whole market. Data is as of 2026-10-26.
Companies above about $300 million in size, ranked by Marvin scores (0-100, relative to each company's own industry). The Healthcare sector, highest Opportunity score first, among companies with a Business Quality score of at least 50; at most 4 per industry.
The stocks, one by one
Nutex Health, Inc. NUTX
Nutex Health, which runs care facilities, pairs revenue growth of 82.4% with an operating margin of 40.6% and a free cash flow margin of 32.4%. That points to fast growth and strong profitability. Debt-to-equity of 0.88 is moderate. Caution: such a high growth rate is unusual and covers just one fiscal year.
Arrowhead Pharmaceuticals, Inc. ARWR
Arrowhead Pharmaceuticals, a biotechnology company, shows revenue growth of 23258.2%, a very large jump in the last fiscal year. It still spends more than it earns, with an operating margin of -33.8% and a free cash flow margin of -11.2%. Caution: return on equity is -68.7%, and no debt figure is available.
Travere Therapeutics, Inc. TVTX
Travere Therapeutics grew revenue by 110.5% and has a gross margin of 98.6%, so it keeps most of each sale after direct costs. Caution: operating margin of -6.8% is slightly negative, return on equity of -177.2% is deeply negative, and free cash flow data is missing.
Iovance Biotherapeutics, Inc. IOVA
Iovance Biotherapeutics reports revenue growth of 60.6% and a gross margin of 48.4%. Its spending still far exceeds its sales. Caution: operating margin of -92.7% and free cash flow margin of -91.2% are deeply negative, and return on equity is -39.3%. No debt figure is available.
Axsome Therapeutics, Inc. AXSM
Axsome Therapeutics shows revenue growth of 65.5% and a free cash flow margin of -9.3%, close to break-even, though its operating margin is -24.0%. Caution: return on equity of -230.1% is negative, and debt-to-equity of 2.70 is on the higher side.
Natera, Inc. NTRA
Natera, a diagnostics company, grew revenue by 35.9% and has a slightly positive free cash flow margin of 3.1%, even though its operating margin is -10.7%. Caution: Business Quality of 56 is toward the lower end of this list, and return on equity of -10.6% is negative.
Glaukos Corporation GKOS
Glaukos, a medical device maker, has revenue growth of 32.3% and a gross margin of 60.7%. Its free cash flow margin of -2.0% is near break-even. Caution: operating margin of -31.6% and return on equity of -27.6% are both negative, and no debt figure is available.
ANI Pharmaceuticals, Inc. ANIP
ANI Pharmaceuticals combines revenue growth of 43.8% with positive margins: 15.4% operating and 17.7% free cash flow. Debt-to-equity of 0.50 is low, and return on equity is 18.1%. Caution: no gross margin is available, and its margins are more modest than some profitable peers here.
TransMedics Group, Inc. TMDX
TransMedics Group, a medical device company, shows revenue growth of 37.1%, a gross margin of 58.7% and return on equity of 29.3%, a profitable picture. Caution: operating margin of 12.2% is modest next to its gross margin, and no debt figure is available.
Oscar Health, Inc. OSCR
Oscar Health, a health plan company, has revenue growth of 27.5% and low debt-to-equity of 0.21. Its free cash flow margin is 28.6%. Caution: operating margin of 3.9% is thin, meaning little profit from each dollar of sales, and Business Quality of 74 is mid-range for this list.
Liquidia Corporation LQDA
Liquidia is profitable on these measures, with an operating margin of 37.4%, a free cash flow margin of 33.4% and return on equity of 71.0%. Caution: growth of 1031.2% is a single-year jump, Business Quality of 68 is middling, and no debt figure is available.
Eli Lilly and Company LLY
Eli Lilly shows revenue growth of 44.7%, a gross margin of 83.4% and return on equity of 78.8%, all strong. Debt-to-equity of 1.62 is moderate. Caution: operating margin and free cash flow margin are missing, so the profit picture is incomplete.
CeriBell, Inc. CBLL
CeriBell, a medical device company, has a gross margin of 88.9% and revenue growth of 36.1%. Caution: operating margin of -68.6% and free cash flow margin of -53.7% are deeply negative, so it is spending far more than it earns. Return on equity is -51.4%.
Guardant Health, Inc. GH
Guardant Health grew revenue by 32.9% and has a gross margin of 65.0%. Caution: operating margin of -39.7% and free cash flow margin of -20.3% are negative, Business Quality of 51 is the lowest on this list, and return on equity and debt data are missing.
PACS Group, Inc. PACS
PACS Group, which runs care facilities, has revenue growth of 29.3%, an operating margin of 7.4% and return on equity of 24.2%. Caution: debt-to-equity of 3.07 is the highest on this list, and free cash flow data is missing.
Common questions
Why do so many of these Healthcare stocks lose money?
Many are biotechnology, diagnostics or device companies that spend heavily on research and growth before sales catch up. Negative margins are common in those industries, so look at the margins and debt alongside the scores.
Does a high Opportunity score mean a stock is a good buy?
No. The score only shows how a company compares with others in its industry today. It is not a recommendation or a forecast, so do your own research before making any decision.
Why are some figures missing for certain companies?
Not every company reports every measure in a form Marvin can use. Gross margin, for example, is often unavailable for health plans and some drug companies. Missing figures mean an incomplete picture, not a good or bad result.
Keep reading
- Top 15 Healthcare Stocks Right Now, Ranked by Marvin Scores
- Top 20 Medical Stocks Ranked by Marvin Scores
- Top 15 Healthcare Companies With the Strongest Businesses
- Top 15 Biotechnology Stocks by Marvin Score
Free account. Build your own AI-made watchlists, follow Marvin's scores and share lists.
Create a free account
Marvin's scores (0-100) compare each company with others in its industry today. Growth and margin figures come from SEC filings. This is general information, not personal investment advice or a recommendation to buy or sell anything. Do your own research.